FOLD Q3 2019 Earnings — Amicus Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FOLDAmicus Therapeutics, Inc.

$5B

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$49M+136.8% YoY

Gross Profit

$43M88.5% margin

Operating Income

-$57M-117.5% margin

Net Income

-$62M-126.7% margin

EPS (Diluted)

$-0.24

QoQ Revenue Growth

+10.5%

Cash Flow

Operating Cash Flow

-$56M

Free Cash Flow

-$60M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$882M

Total Liabilities

$334M

Stockholders' Equity

$548M

Cash & Equivalents

$166M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$49M	$21M	+136.8%
Gross Profit	$43M	$16M	+165.1%
Operating Income	-$57M	-$156M	+63.3%
Net Income	-$62M	-$159M	+61.2%

Geographic Segments

Non-US

$33M68%

UNITED STATES

$15M32%